Concepedia

Publication | Closed Access

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

DOI

155

Citations

23

References

2023

Year

Andreas Reif, István Bitter, Jozefien Buyze, Kerstin Cebulla, Richard Frey, Dong‐Jing Fu, Tetsuro Ito, Yerkebulan Kambarov, Pierre‐Michel Llorca, Albino J. Oliveira‐Maia,
New England Journal of Medicine

Abstract

In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).

References

YearCitations

Page 1